AZD1386 Japanese Multiple Ascending Dosing Study
A Phase I, Randomised, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1386 in Healthy Japanese Young and Elderly Subjects After Oral Multiple Doses.
  • Phase

    Phase 1
  • Study Type

  • Status

    Completed No Results Posted
  • Intervention/Treatment

    azd1386 ...
  • Study Participants

This is a single centre, double-blind, randomised, parallel group, placebo controlled study to assess the safety, tolerability and pharmacokinetics of AZD1386 when given as multiple doses to 32 (24 healthy young and 8 healthy elderly) Japanese subjects. For young healthy subjects (aged ≥20 to ≤45 inclusive) 3 consecutive multiple ascending dose panels are planned. For elderly healthy subjects (aged ≥65 to≤80 inclusive) 1 multiple dose panel is planned.
Study Started
Jun 30
Study Completion
Sep 30
Last Update
Sep 30

Drug AZD1386

Oral admin. of doses at 11 days through a 12 days period.

Drug Placebo

Oral admin. of doses at 11 days through a 12 days period.

AZD1386 Experimental

4 groups receiving a specified volume of the active component AZD1386 at different points of time.

Placebo Placebo Comparator

Included in each dose group


Inclusion Criteria:

Healthy Japanese males or females young (≥20 to ≤45 years inclusive) or elderly (≥65 to ≤80 years inclusive). Female subjects must be surgically sterile or post-menopausal.
Body Mass Index (BMI) of ≥19 to ≤ 27 kg/m2 and weight of ≥45 to ≤90 kg
Clinically normal physical findings including heart rate > 45 bpm and laboratory values and normal resting ECG

Exclusion Criteria:

History of somatic or psychiatric disease/condition, which may interfere with the objectives of the study as judged by the investigator
A family history of short or long QT syndrome (SQTS) or sudden cardiac death (SCD) amongst first degree relatives
Subjects with orthostatic hypotension defined as a decrease of ≥ 25mmHg systolic blood pressure and/or a decrease of ≥15mmHg diastolic blood pressure within 5 minutes when going from a supine to standing position
Clinically significant illness or clinically relevant trauma within 2 weeks prior to the administration of the investigational product as judged by the investigator
No Results Posted